Whitehawk Therapeutics (NASDAQ:WHWK) Stock Falls 4.6% - Here's What Happened

Whitehawk Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Whitehawk Therapeutics shares fell 4.6% to $3.30 in midday trading, with trading volume 54% above its average.
  • Analyst sentiment remains generally positive: seven analysts rate the stock a Buy, one rates it a Sell, and the consensus rating is “Moderate Buy” with an $8.33 average price target.
  • The company reported a quarterly loss of $0.20 per share, beating the $0.30 loss expected by analysts, while institutional investors and hedge funds own 52.08% of the stock.
  • Five stocks we like better than Whitehawk Therapeutics.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report)'s share price was down 4.6% during mid-day trading on Thursday. The company traded as low as $3.25 and last traded at $3.30. Approximately 523,161 shares changed hands during trading, an increase of 54% from the average session volume of 339,868 shares. The stock had previously closed at $3.46.

Wall Street Analysts Forecast Growth

WHWK has been the subject of a number of research reports. Leerink Partners began coverage on Whitehawk Therapeutics in a research report on Monday, July 13th. They set an "outperform" rating and a $9.00 price target for the company. Stifel Nicolaus initiated coverage on Whitehawk Therapeutics in a report on Wednesday, September 30th. They issued a "buy" rating and a $9.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research note on Wednesday, September 2nd. Finally, Wall Street Zen raised Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $8.33.

Read Our Latest Stock Report on WHWK

Whitehawk Therapeutics Stock Down 4.6%

The company's 50-day moving average price is $3.89 and its 200-day moving average price is $3.82. The firm has a market cap of $188.13 million, a price-to-earnings ratio of -2.95 and a beta of 0.92.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.10. Analysts predict that Whitehawk Therapeutics, Inc. will post -1.00 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Montanova Capital LLC increased its holdings in shares of Whitehawk Therapeutics by 16.2% in the second quarter. Montanova Capital LLC now owns 4,300,000 shares of the company's stock valued at $19,694,000 after purchasing an additional 600,000 shares during the last quarter. Two Sigma Securities LLC purchased a new position in Whitehawk Therapeutics during the second quarter worth approximately $46,000. Bank of America Corp DE purchased a new position in Whitehawk Therapeutics during the second quarter worth approximately $159,000. ADAR1 Capital Management LLC acquired a new position in Whitehawk Therapeutics during the second quarter worth $6,144,000. Finally, BlackRock Inc. acquired a new position in Whitehawk Therapeutics during the second quarter worth $8,807,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

About Whitehawk Therapeutics

(Get Free Report)

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company's activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company's specific pipeline, operating geographies and leadership is limited.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Whitehawk Therapeutics Right Now?

Before you consider Whitehawk Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Whitehawk Therapeutics wasn't on the list.

While Whitehawk Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines